Table 1.
Treatment | Description | Benefits | Limitations |
---|---|---|---|
Non-surgical methods | Analgesics, weight loss, physical re-education, physical therapy, complementary medicine (e.g., acupuncture) | No surgery necessary Relatively inexpensive |
Palliative treatment options Chronic analgesic use potential |
Arthroscopic chondroplasty | Arthroscopic resection of detached cartilage fragments to prevent further joint irritation and damage | Rapid, minimally invasive procedureImmediate weight-bearing possible | Palliative treatment Benefits not proven Brief pain relief |
MF 1 | Arthroscopic procedure to create small lesions in the osteochondral interface to direct osteoprogenitor cells into damaged cartilage tissue | No graft required for defects < 2 cm2 Rapid recovery |
Fibrocartilage formation potential Variable functional outcomes Rapid deterioration |
Mosaicoplasty | Osteochondral autografts harvested from patient non-loaded zones of the joint | Optimal for small lesions (1–4 cm2) Pain relief |
Sub-optimal surrounding tissue graft adherence Graft-site morbidity |
ACI 2 | Autologous cultured and expanded chondrocytes implanted in the lesion under a tissue flap | Hyaline cartilage formation potential Extensive lesion treatment (<10 cm2) |
Graft delamination Periosteal hypertrophy Qualitative variability of regenerated tissue Onerous protocol |
MACI 3 | Autologous cultured and expanded chondrocytes seeded onto 3D scaffolds and implanted into defect | Treatment of large lesions Hyaline cartilage formation potential Limited periosteal hypertrophy |
Graft delamination Limited integration Qualitative variability of regenerated tissue Onerous protocol |
Joint arthroplasty | Replacement of arthritic joint with an artificial implant | Pain relief Functional resurgence potential |
Infectious risk Functional outcome variability Implant wear or loosening |
1 Microfracture, 2 Autologous chondrocyte implantation, 3 Matrix-assisted autologous chondrocyte transplantation.